Showing results (31-40 of 259) with videos related to
Sort By:
Pageof 26
Statistics in Biosciences|March 20, 2023
Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention ModalitiesHolly Janes, Yifan Zhu, Elizabeth R BrownStatistics in Medicine|June 27, 2015
Designing a study to evaluate the benefit of a biomarker for selecting patient treatmentHolly Janes, Marshall D Brown, Margaret S PepeStatistics in Medicine|November 30, 2004
Identifying target populations for screening or not screening using logic regressionHolly Janes, Margaret Pepe, Charles Kooperberg, et al.Journal of the National Cancer Institute|April 1, 2014
Net risk reclassification p values: valid or misleading?Margaret S Pepe, Holly Janes, Christopher I LiBiometrics|November 17, 2019
Statistical inference for net benefit measures in biomarker validation studiesTracey L Marsh, Holly Janes, Margaret S PepeCurrent Opinion in HIV and AIDS|October 28, 2010
Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineGlenda Gray, Susan Buchbinder, Ann DuerrOpen Forum Infectious Diseases|July 26, 2021
Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United StatesLaura Matrajt, Holly Janes, Joshua T Schiffer, et al.Biostatistics (Oxford, England)|September 22, 2016
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trialsYing Huang, Peter B Gilbert, Rong Fu, et al.The International Journal of Biostatistics|April 4, 2014
An approach to evaluating and comparing biomarkers for patient treatment selectionHolly Janes, Marshall D Brown, Ying Huang, et al.Statistics in Medicine|April 2, 2026
Comparing HIV Vaccine Immunogenicity Across Trials With Different Populations and Study DesignsYutong Jin, Alex Luedtke, Zoe Moodie, et al.Pageof 26